Skip to main content

CME Group Inc. (CME) Stock Analysis

SellModerate Confidence

Financial Services · Financial Data & Stock Exchanges

Sell if holding. Analyst target reached at $287.32 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CME Globex electronic platform (93.0%).

CME Group operates CME, CBOT, NYMEX, and COMEX futures and options exchanges plus BrokerTec and EBS for fixed income and FX trading, offering derivatives across interest rates, equity indices, FX, agricultural commodities, energy, metals, and cryptocurrencies. Revenue is... Read more

$287.32+6.7% A.UpsideScore 5.5/10#6 of 11 Financial Data & Stock Exchanges
Stop $275.14Target $306.43(resistance)A.R:R -0.8:1
Analyst target$306.60+6.7%15 analysts
$306.43our TP
$287.32price
$306.60mean
$230
$353

Sell if holding. Analyst target reached at $287.32 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CME Globex electronic platform (93.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.

Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity 82d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (3/4)
Risks
Concentration risk — Product: CME Globex electronic platform (93.0%)
Analyst target reached - limited upside remaining
Expensive valuation

Key Metrics

P/E (TTM)24.5
P/E (Fwd)22.3
Mkt Cap$104.1B
EV/EBITDA22.0
Profit Mgn63.3%
ROE15.9%
Rev Growth14.4%
Beta0.30
Dividend1.81%
Rating analysts20

Quality Signals

Piotroski F8/9

Options Flow

P/C1.67bearish
IV36%normal
Max Pain$355+23.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductCME Globex electronic platform93%
    10-K Item 1A: 'In 2025, 93% of our overall contract volume was generated through electronic trading on our CME Globex electronic platform.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Ev Ebitda
0.0
Peg Ratio
2.6
Analyst Target
4.0
Pe
5.1
Forward Pe
5.8
Forward P/E: 22.3xPEG: 4.92
GatesMomentum 4.4<4.5A.R:R -0.8=NEGATIVEInsider activity: OKNo SEC red flagsEARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
37 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $274.60Resistance $312.68

Price Targets

$275
$306
A.Upside+6.7%
A.R:R-0.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Target reached (-3.9% upside)
! Momentum score 4.4/10 — below 4.5 minimum
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-22 (82d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CME stock a buy right now?

Sell if holding. Analyst target reached at $287.32 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CME Globex electronic platform (93.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $275.14. Score 5.5/10, moderate confidence.

What is the CME stock price target?

Take-profit target: $306.43 (+6.7% upside). Prior stop was $275.14. Stop-loss: $275.14.

What are the risks of investing in CME?

Concentration risk — Product: CME Globex electronic platform (93.0%); Analyst target reached - limited upside remaining; Expensive valuation.

Is CME overvalued or undervalued?

CME Group Inc. trades at a P/E of 24.5 (forward 22.3). TrendMatrix value score: 3.2/10. Verdict: Sell.

What do analysts say about CME?

20 analysts cover CME with a consensus score of 3.5/5. Average price target: $307.

What does CME Group Inc. do?CME Group operates CME, CBOT, NYMEX, and COMEX futures and options exchanges plus BrokerTec and EBS for fixed income...

CME Group operates CME, CBOT, NYMEX, and COMEX futures and options exchanges plus BrokerTec and EBS for fixed income and FX trading, offering derivatives across interest rates, equity indices, FX, agricultural commodities, energy, metals, and cryptocurrencies. Revenue is substantially derived from transaction fees; 93% of 2025 contract volume was generated electronically via CME Globex.

Related stocks: NDAQ (Nasdaq, Inc.) · MCO (Moody's Corporation) · SPGI (S&P Global Inc.) · CBOE (Cboe Global Markets, Inc.) · TRU (TransUnion)